JERUSALEM, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that management will participate in the following investor conferences in November 2023.
| Event: | Emerging Growth Conference |
| Format: | Company presentation and 1-on-1 meetings |
| Date: | Thursday, November 2nd, 2023 |
| Time | 3:25 – 3:35 PM ET |
| Location: | Virtual |
| Event: | Jefferies London Healthcare Conference |
| Format: | Company presentation and 1-on-1 meetings |
| Date: | Wednesday, November 15th, 2023 |
| Time: | 10:00 AM GMT |
| Location: | London |
| Event: | Piper Sandler 35th Annual Healthcare Conference |
| Format: | Fireside chat and 1-on-1 meetings |
| Date: | Tuesday, November 28th, 2023 |
| Time: | 11:30 AM ET |
| Location: | New York, NY |
Please reach out to your Jefferies and Piper Sandler representatives to schedule, and register here to ensure you are able to attend the Emerging Growth conference and receive any updates that are released.
https://goto.webcasts.com/starthere.jsp?ei=1603286&tp_key=f701725cb0&sti=drts
If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available on EmergingGrowth.com and on the Emerging Growth YouTube Channel, http://www.YouTube.com/EmergingGrowthConference.
About Alpha Tau Medical Ltd.
Founded in 2016, Alpha Tau is an Israeli medical device company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.
About Alpha DaRT™
Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.
Investor Relations Contact:
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$3.95 |
| Daily Change: | -0.12 -2.83 |
| Daily Volume: | 28,799 |
| Market Cap: | US$336.350M |
December 04, 2025 December 02, 2025 November 20, 2025 October 21, 2025 September 02, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
